Ocera Therapeutics
About Ocera Therapeutics
Ocera Therapeutics is a Healthcare company based in San Diego (United States) founded in 2005, and was acquired by Mallinckrodt Pharmaceuticals in November 2017. Ammonia scavenger drug for patients with acute and chronic liver disease. Ocera Therapeutics has raised $64 million across 7 funding rounds from investors including Mallinckrodt Pharmaceuticals, RA Capital and Gimv. The company was acqui-hired. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Hepatic disorders. Its legal entity is OCERA THERAPEUTICS, INC. Its competitors include NGM Biopharmaceuticals, Nimbus Therapeutics and Altimmune; 3 of its 3 listed competitors have raised funding.
Company details
Ocera, acquired by Mallinckrodt Pharmaceuticals in 2017, is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need. Oceras lead drug candidate OCR-002 is a novel ammonia scavenger which rapidly removes ammonia from the blood. Elevated ammonia is believed to be one of the primary causes of hepatic encephalopathy (HE). OCR-002 is the subject of STOP-HE, a Company-sponsored Phase 2b trial, and two investigator-sponsored Phase 2a trials. OCR-002 has received Orphan Drug designation in both the U.S. and Europe and has been granted Fast Track status by the U.S. Food and Drug Administration.
- Headquarters San Diego, United States
- Stage Public
- SectorsHealthcare
- Website ocerainc.com
- Social LinkedIn
- Acquired by Mallinckrodt Pharmaceuticals (Nov 2017)
- Legal Name Ocera Therapeutics, Inc.
- Total Equity Funding$64M (USD)
in 7 rounds
- Latest Funding Round$28M (USD), Post-IPO
Nov 2013
- InvestorsMallinckrodt Pharmaceuticals
& 18 more
- Acquired byMallinckrodt Pharmaceuticals
(Nov 2017)
Funding Insights of Ocera Therapeutics
Ocera Therapeutics has successfully raised a total of $64M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $28 million completed in November 2013. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $64M
- Total Rounds 7
- Last Round Post-IPO — $28M
- First Round $14.5M
(Jan 2006)
- Investors Count 18
All 7 funding rounds of Ocera Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2013 | $28M | Post-IPO | – | – | |
| Jul 2013 | $20M | Post-IPO | – | – | |
| Apr 2012 | $1.5M | Post-IPO | – | – | – |
| Jun 2010 | $2M | Series C | – | – | – |
| Feb 2008 | $35.5M | Series C | – | Greenspring Associates | |
| Jul 2006 | $12M | Series B | – | – | |
| Jan 2006 | $14.5M | Series A | – | – |
19 investors in total: 19 institutional.
Investors in Ocera Therapeutics
Ocera Therapeutics has secured backing from 19 investors, including venture fund and institutional investors. Prominent investors backing the company include Mallinckrodt Pharmaceuticals, RA Capital and Gimv.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm focused on tech sectors | venrock.com | Palo Alto, United States | ||
Private equity firm focused on company buyouts | gppfunds.com | Greenwich, United States | ||
Investment management in biotech, technology, energy, shipping, financials, and litigation sectors. | 2003 | qvt.com | ||
Early-stage investing in IT and healthcare ventures. | interwest.com | |||
Life science & tech focused VC firm investing in companies in the US | threearchpartners.com | San Mateo, United States | ||
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
Healthcare ecosystem is supported through investment and innovation by Deerfield. | deerfield.com | New York, United States | ||
Life science & tech focused VC firm investing in the US | domainvc.com | Princeton, United States | ||
| tm-partners.com | ||||
Biotech funding, drug development support, and investment in life sciences. | sofinnova.com |
Investor details for Ocera Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Ocera Therapeutics
5 dated milestones of Ocera Therapeutics across 12 years, from founding to its latest funding, stage changes and deals.
- Founded Ocera Therapeutics is founded.
- Funding First funding round of $14.5M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $28.0M.
- Exit Acquired by Mallinckrodt Pharmaceuticals.
Competitors of Ocera Therapeutics
Ocera Therapeutics has 3 listed competitors in our database, 3 of them funded. They include NGM Biopharmaceuticals, Nimbus Therapeutics and Altimmune.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ngmbio.com | 2007 | San Francisco, United States | $358.87M | 225 | Biologics are developed for cardio-metabolic and liver diseases. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| altimmune.com | 1997 | Gaithersburg, United States | $58M | 17 | Vaccines for infectious diseases and solid tumors are developed. |
Detailed competitors of Ocera Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Ocera Therapeutics (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ocera Therapeutics
Complete news archive for Ocera Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ocera Therapeutics
Ocera Therapeutics was founded in 2005 and raised its 1st funding round 1 year after it was founded.
Ocera Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Ocera Therapeutics is a funded company, having raised a total of $64M across 7 funding rounds to date. The company's 1st funding round was a Series A of $14.5M, raised on Jan 2006.
Ocera, acquired by Mallinckrodt Pharmaceuticals in 2017, is a clinical stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for patients with acute and chronic liver disease, an area of high unmet medical need. Oceras lead drug candidate OCR-002 is a novel ammonia scavenger which rapidly removes ammonia from the blood. Elevated ammonia is believed to be one of the primary causes of hepatic encephalopathy (HE). OCR-002 is the subject of STOP-HE, a Company-sponsored Phase 2b trial, and two investigator-sponsored Phase 2a trials. OCR-002 has received Orphan Drug designation in both the U.S. and Europe and has been granted Fast Track status by the U.S. Food and Drug Administration.
Ocera Therapeutics's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and Altimmune.
Ocera Therapeutics has 19 investors. Key investors include Mallinckrodt Pharmaceuticals, RA Capital, Gimv, Greenspring Associates, and Venrock.
Ocera Therapeutics operates through Ocera Therapeutics, Inc..
Yes. Ocera Therapeutics was acquired by Mallinckrodt Pharmaceuticals in November 2017.